CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations > Reports & Downloads > Development Pipeline

Development Pipeline

Oncology

Development code Indication
* Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG435 Breast cancer * Filed
Oct.09
bevacizumab
Avastin®
Injection
Roche
Avastin®
Humanized anti-VEGF
(Vascular Endothelial Growth Factor)
monoclonal antibody
Colon cancer (adjuvant) * Phase III
Multinational study
Gastric cancer * Phase III
Multinational study
Breast cancer
(adjuvant) *
Phase III
Multinational study
Glioblastoma * Phase III
Multinational study
Glioblastoma (relapsed) * Phase II
EPOCH Chemotherapy-induced anemia * Filed
Nov.09
epoetin beta
Epogin®
Injection
In-house Recombinant human erythropoietin
RG340 Gastric cancer * Filed
Mar.10
capecitabine
Xeloda®
Oral
Roche
Xeloda®
Antimetabolite,
5-FU derivative
RG597 Gastric cancer * Filed
Mar.10
trastuzumab
Herceptin®
Injection
Roche
Herceptin®
Humanized anti-HER2 monoclonal antibody
RG1415 Pancreatic cancer * Filed
Sep.09
erlotinib
Tarceva®
Oral
Roche / OSI
Tarceva®
EGFR tyrosine kinase inhibitor
Non-small cell lung cancer (1st line) * Phase II
RG1273 Breast cancer Phase III
Multinational study
pertuzumab

Injection
Roche Humanized HER dimerization inhibitory monoclonal antibody
MRA Pancreatic cancer * Phase I / II tocilizumab
Actemra®
Injection
In-house

(Roche)
Humanized anti-human IL-6 receptor monoclonal antibody
TP300 Gastric cancer, etc Phase II
Overseas


Injection
In-house Topoisomerase I inhibitor
CIF
(RG7167)
Solid tumors Phase I

Oral
In-house

(Roche)
MEK inhibitor
Phase I
Overseas
CKI27
(RG7304)
Solid tumors Phase I

Oral
In-house

(Roche)
Raf and MEK dual inhibitor
Phase I
Overseas
GC33 Liver cancer Phase I Overseas

Injection
In-house Humanized anti-Glypican-3 monoclonal antibody
GA101
(RG7159)
Non-Hodgkin's lymphoma Phase I

Injection
GlycArt Humanized anti-CD20 monoclonal antibody
RG3502 Breast cancer Phase I

Injection
Roche HER2 antibody-drug conjugate

Bone and Joint Diseases

Development code Indication
* Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
ED-71 Osteoporosis Filed
Oct.09
eldecalcitol

Oral
In-house

(Taisho Pharmaceutical)
Active Vitamin D3 derivative
MRA Systemic onset juvenile idiopathic arthritis (sJIA) * Phase III
Overseas
tocilizumab
Actemra® / RoActemra®(EU)
Injection
In-house

(Roche)
Humanized anti-human IL-6 receptor monoclonal antibody
Rheumatoid arthritis (new formulation : subcutaneous injection) Phase III tocilizumab
Actemra®
Injection
RG1594 Rheumatoid arthritis Phase III Multinational study ocrelizumab

Injection
Roche Humanized anti-CD20 monoclonal antibody
RG484 Osteoporosis Phase II / III ibandronate sodium hydrate

Injection
Roche
Boniva® (US) / Bonviva® (EU)
(Taisho Pharmaceutical)
Bisphosphonate
Phase II ibandronate sodium hydrate

Oral

Renal Diseases

Development code Indication
* Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG744 Renal anemia Filed
Jul.09


Injection
Roche
Mircera®
Continuous erythropoietin receptor activator

Transplant, Immunology and Infectious Diseases

Development code Indication
* Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG964 Compensated liver cirrhosis caused by hepatitis C virus * Phase II / III ribavirin
Copegus®
Oral
Roche
Copegus®
Anti-viral agent, in combination with Pegasys®
RG442     peginterferon alfa-2a
Pegasys®
Injection
Roche
Pegasys®
Peginterferon alfa-2a agent (recombinant)
Chronic hepatitis B * Phase II / III
NA808 Chronic hepatitis C Phase I

Injection
In-house Serine palmitoyltransferase inhibitor
Phase I Overseas
NTZ Chronic hepatitis C Development
suspended
nitazoxanide

Oral
Romark Laboratories
Alinia®
Thiazolide compound

Other Diseases

Development code Indication
* Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
EPOCH Predeposit of autologous blood transfusion * Approved
Jun.10
epoetin beta
Epogin®
Injection
In-house Recombinant human erythropoietin
CSG452
(RG7201)
Type II diabetes Phase II Multinational study

Oral
In-house

(Roche)
SGLT2 inhibitor
RG1583
(ITM-077)
Type II diabetes Phase II taspoglutide

Injection
Roche / Ipsen

(Teijin)
GLP-1 analogue
RG1678 Schizophrenia Phase II Multinational study

Oral
Roche GLYT1 inhibitor
RG1450 Alzheimer's disease Phase I gantenerumab

Injection
Roche / Morphosys Human anti-amyloid-beta monoclonal antibody

To view PDF files,
you will need Adobe® Reader® which is available as a free download.